
    
      The purpose of this study is to perform a randomized Phase II evaluation of
      Carboplatin/Paclitaxel with or without Trastuzumab (Herceptin) in patients with HER2/neu+
      advanced stage/recurrent disease with an emphasis on determining the progression free
      survival in USPC patients and assessing immunologic markers predictive of trastuzumab
      response.
    
  